Breaking bad biofilms
Synspira’s glycopolymers target mechanisms driving decline in pulmonary disorders
Synspira LLC is developing glycopolymers against pulmonary disorders by targeting three mechanisms that exacerbate pulmonary decline: bacteria themselves, the mucus and biofilms that protect them and inflammation that leads to lasting tissue damage.
Synspira in-licensed its technology from therapeutic polysaccharide company Synedgen Inc. in 2017 to develop polycationic glycopolymers in pulmonary indications. Lead product SNSP113 is a derivative of poly-N-acetyl-glucosamine to treat pulmonary exacerbations in
